CD274 and colorectal carcinoma: One study analyzed over 6000 CRC cases, 95% of which were classified as MSS, and observed that 2.9% of MSS tumors exhibited high TMB and, within this subset of tumors, 54% responded to anti‐PD‐L1 immunotherapy (Fabrizio et al., 2018).